Skip Navigation


NDT Advance Access originally published online on January 18, 2007
Nephrology Dialysis Transplantation 2007 22(4):981-988; doi:10.1093/ndt/gfl814
This Article
Right arrow Full Text Freely available
Right arrow FREE Full Text (PDF) Freely available
Right arrow All Versions of this Article:
22/4/981    most recent
gfl814v1
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Related articles in NDT
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Search for citing articles in:
ISI Web of Science (2)
Right arrowRequest Permissions
Right arrow Disclaimer
Google Scholar
Right arrow Articles by Wiecek, A.
Right arrow Articles by Chudek, J.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Wiecek, A.
Right arrow Articles by Chudek, J.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

© The Author [2007]. Published by Oxford University Press on behalf of ERA-EDTA. All rights reserved. For Permissions, please email: journals.permissions@oxfordjournals.org

Adiponectin—an adipokine with unique metabolic properties

Andrzej Wiecek, Marcin Adamczak and Jerzy Chudek

Department of Nephrology, Endocrinology and Metabolic Diseases, Medical University of Silesia, Katowice, Poland

Correspondence and offprint requests to: Prof. dr hab. med. Andrzej Wiecek, FRCP (Edin), Department of Nephrology, Endocrinology and Metabolic Diseases, Medical University of Silesian, Katowice, ul. Francuska 20/24, 40-027 Katowice, Poland. Email: awiecek@spskm.katowice.pl

Keywords: adipocytes; adipokines; adiponectin

The first 150 words of the full text of this article appear below.



   Introduction
 
The epidemic of visceral obesity and its complications: insulin resistance, type 2 diabetes mellitus, obesity-related arterial hypertension, and obesity-related glomerulopathy is a challenging health problem for modern societies in the 21st century.

In the last decade, adipose tissue was recognized as an active endocrine organ that can affect the function of other organs and is an important source of several hormones: cytokines, chemokines, growth factors and complement proteins called ‘adipokines’ or ‘adipocytokines’ (for review see [1,2]). Many of them may influence the function of the cardiovascular system. An incomplete list of such adipokines is presented in Table 1.


View this table:



  		Table 1. List of hormones, cytokines, chemokines, growth factors and complement proteins produced by the adipose tissue

 
The role of one very promising adipokine—adiponectin, in the pathogenesis of cardiovascular and renal diseases is discussed in this review.



   Adiponectin—a unique adipokine with anti-atherogenic, anti-inflammatory and insulin-sensitizing properties
 
Adiponectin is a 30 kDa protein hormone secreted almost exclusively by adipocytes . . . [Full Text of this Article]



   Adiponectin in chronic kidney disease (CKD) patients
 


   Plasma adiponectin concentration and cardiovascular morbidity in patients with CKD
 


   How to increase plasma adiponectin concentration?
 

Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?

Related articles in NDT:

In this issue ...

NDT 2007 22: i. [Extract] [FREE Full Text]